Literature DB >> 18502301

Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial.

S Bellary1, J P O'Hare, N T Raymond, A Gumber, S Mughal, A Szczepura, S Kumar, A H Barnett.   

Abstract

BACKGROUND: Delivery of high-quality, evidence-based health care to deprived sectors of the community is a major goal for society. We investigated the effectiveness of a culturally sensitive, enhanced care package in UK general practices for improvement of cardiovascular risk factors in patients of south Asian origin with type 2 diabetes.
METHODS: In this cluster randomised controlled trial, 21 inner-city practices in the UK were assigned by simple randomisation to intervention (enhanced care including additional time with practice nurse and support from a link worker and diabetes-specialist nurse [nine practices; n=868]) or control (standard care [12 practices; n=618]) groups. All adult patients of south Asian origin with type 2 diabetes were eligible. Prescribing algorithms with clearly defined targets were provided for all practices. Primary outcomes were changes in blood pressure, total cholesterol, and glycaemic control (haemoglobin A1c) after 2 years. Analysis was by intention to treat. This trial is registered, number ISRCTN 38297969.
FINDINGS: We recorded significant differences between treatment groups in diastolic blood pressure (1.91 [95% CI -2.88 to -0.94] mm Hg, p=0.0001) and mean arterial pressure (1.36 [-2.49 to -0.23] mm Hg, p=0.0180), after adjustment for confounders and clustering. We noted no significant differences between groups for total cholesterol (0.03 [-0.04 to 0.11] mmol/L), systolic blood pressure (-0.33 [-2.41 to 1.75] mm Hg), or HbA1c (-0.15% [-0.33 to 0.03]). Economic analysis suggests that the nurse-led intervention was not cost effective (incremental cost-effectiveness ratio pound28 933 per QALY gained). Across the whole study population over the 2 years of the trial, systolic blood pressure, diastolic blood pressure, and cholesterol decreased significantly by 4.9 (95% CI 4.0-5.9) mm Hg, 3.8 (3.2-4.4) mm Hg, and 0.45 (0.40-0.51) mmol/L, respectively, and we recorded a small and non-significant increase for haemoglobin A1c (0.04% [-0.04 to 0.13]), p=0.290).
INTERPRETATION: We recorded additional, although small, benefits from our culturally tailored care package that were greater than the secular changes achieved in the UK in recent years. Stricter targets in general practice and further measures to motivate patients are needed to achieve best possible health-care outcomes in south Asian patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502301     DOI: 10.1016/S0140-6736(08)60764-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  42 in total

1.  Replication of 13 genome-wide association (GWA)-validated risk variants for type 2 diabetes in Pakistani populations.

Authors:  S D Rees; M Z I Hydrie; A S Shera; S Kumar; J P O'Hare; A H Barnett; A Basit; M A Kelly
Journal:  Diabetologia       Date:  2011-02-25       Impact factor: 10.122

2.  Nurse-led management of hypertension.

Authors:  Christopher E Clark; Lindsay F P Smith; Rod S Taylor; John L Campbell
Journal:  Br J Gen Pract       Date:  2010-03       Impact factor: 5.386

Review 3.  Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care.

Authors:  Greg Weeks; Johnson George; Katie Maclure; Derek Stewart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-22

4.  Ethnic and social disparity in glycaemic control in type 2 diabetes; cohort study in general practice 2004-9.

Authors:  Gareth D James; Peter Baker; Ellena Badrick; Rohini Mathur; Sally Hull; John Robson
Journal:  J R Soc Med       Date:  2012-03-06       Impact factor: 5.344

5.  Economics of Community Health Workers for Chronic Disease: Findings From Community Guide Systematic Reviews.

Authors:  Verughese Jacob; Sajal K Chattopadhyay; David P Hopkins; Jeffrey A Reynolds; Ka Zang Xiong; Christopher D Jones; Betsy J Rodriguez; Krista K Proia; Nicolaas P Pronk; John M Clymer; Ron Z Goetzel
Journal:  Am J Prev Med       Date:  2019-03       Impact factor: 5.043

6.  Clinical characteristics, modalities and complications of diabetic patients with migration background at a Central European University Clinic.

Authors:  Ammon Handisurya; Dagmar Bancher-Todesca; Majid Reza Kamyar; Rosa Lemmens-Gruber; Alexandra Kautzky-Willer
Journal:  Wien Med Wochenschr       Date:  2011-03-07

7.  Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys.

Authors:  Emmanuela Gakidou; Leslie Mallinger; Jesse Abbott-Klafter; Ramiro Guerrero; Salvador Villalpando; Ruy Lopez Ridaura; Wichai Aekplakorn; Mohsen Naghavi; Stephen Lim; Rafael Lozano; Christopher J L Murray
Journal:  Bull World Health Organ       Date:  2010-11-22       Impact factor: 9.408

8.  The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D).

Authors:  K Winkley; S M Thomas; S Sivaprasad; M Chamley; D Stahl; K Ismail; S A Amiel
Journal:  Diabetologia       Date:  2013-03-14       Impact factor: 10.122

9.  Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study.

Authors:  Neil T Raymond; Lakshminarayanan Varadhan; Dilini R Reynold; Kate Bush; Sailesh Sankaranarayanan; Srikanth Bellary; Anthony H Barnett; Sudhesh Kumar; J Paul O'Hare
Journal:  Diabetes Care       Date:  2008-12-15       Impact factor: 19.112

10.  The promoter polymorphism -232C/G of the PCK1 gene is associated with type 2 diabetes in a UK-resident South Asian population.

Authors:  Simon D Rees; Abigail C Britten; Srikanth Bellary; J Paul O'Hare; Sudhesh Kumar; Anthony H Barnett; M Ann Kelly
Journal:  BMC Med Genet       Date:  2009-09-02       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.